1-[3-(4-Fluorophenoxy)propyl]-I+/--(4-fluorophenyl)-4-piperidinemethanol | 160296-39-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-[3-(4-Fluorophenoxy)propyl]-I+/--(4-fluorophenyl)-4-piperidinemethanol
• 英文别名: [1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl]-(4-fluorophenyl)methanol
• CAS: 160296-39-9
• 化学式: C₂₁H₂₅F₂NO₂
• 分子量: 361.432
• InChiKey: QZKLNOJGEMHCSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(3-氯丙氧基)-4-氟苯 在 sodium tetrahydroborate 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 48.0h， 生成 1-[3-(4-Fluorophenoxy)propyl]-I+/--(4-fluorophenyl)-4-piperidinemethanol
  参考文献：
  名称：

  7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics

  摘要：

  Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)- a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1-piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.

  DOI：

  10.1021/jm950894b

文献信息

• Sigma ligands for use in the prevention and/or treatment of postoperative pain
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2353598A1

  公开（公告）日：2011-08-10

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

  本发明涉及使用sigma配体，特别是公式（I），（II）或（III）的sigma配体，以预防和/或治疗由手术引起的急性和慢性疼痛，特别是手术组织损伤引起的表浅和/或深层疼痛，以及周围神经病理性疼痛，神经痛，触痛，烧伤性痛，痛觉过敏，疼痛过敏，神经炎或手术过程引起的神经病变。
• Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2388005A1

  公开（公告）日：2011-11-23

  The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.

  本发明是指使用σ配体，最好是式(I)的σ配体，来预防或治疗由化疗药物或放射性诱发的呕吐，特别是由紫杉类、长春花生物碱或铂类化疗药物诱发的呕吐。
• Use of sigma ligands in opioid-induced hyperalgesia
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2415471A1

  公开（公告）日：2012-02-08

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

  本发明是指使用σ配体，特别是式(I)的σ配体来预防和/或治疗与阿片类药物治疗相关的阿片类药物诱导的痛觉减退（OIH）。
• Use of sigma ligands in bone cancer pain
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2460519A1

  公开（公告）日：2012-06-06

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to bone cancer.

  本发明是指使用σ配体，特别是式(I)的σ配体来预防和/或治疗与骨癌相关的疼痛。
• USE OF SIGMA LIGANDS IN BONE CANCER PAIN
  申请人：Laboratorios del Dr. Esteve, S.A.

  公开号：EP2646025B1

  公开（公告）日：2017-03-15